A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Clinical trial NCT05068206 · UNKNOWN

Trial details

NCT number: NCT05068206
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Metastatic Colorectal Cancer

Start date: 2021-10-08
Primary completion: 2023-12-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.